CADTH | Evidence Driven
CADTH | Evidence Driven

Reimbursement Review Reports

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Export to CSV
Brand Name Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Beqvez fidanacogene elaparvovec Hemophilia B Reimburse with clinical criteria and/or conditions Active
Prevymis letermovir Cytomegalovirus infection (CMV), prophylaxis Active
TBC lebrikizumab atopic dermatitis Active
Keytruda pembrolizumab Gastric or gastroesophageal junction adenocarcinoma Active
Ultomiris ravulizumab Neuromyelitis optica spectrum disorder (NMOSD) Reimburse with clinical criteria and/or conditions Active
Verzenio abemaciclib Adjuvant treatment of HR-positive, HER2-negative early breast cancer Active
Keytruda pembrolizumab Biliary tract carcinoma Active
Qulipta atogepant Migraine, prevention Active
Tagrisso osimertinib Non-small cell lung cancer Active
N/A Pembrolizumab Melanoma (Skin) Active
Last Updated : April 28, 2024